新辅助联合辅助瑞拉利单抗与纳武利尤单抗治疗可切除黑色素瘤的长期生存与生物标志物分析
该II期临床试验评估新辅助序贯辅助纳武利尤单抗联合瑞拉利单抗治疗可切除III/IV期黑色素瘤,中位随访47个月,4年无事件生存率80%,达主要病理缓解者95%无事件。基因表达分析发现基线免疫调节通路上调与MPR相关,B7-H3高表达与耐药相关。
要点
- 新辅助后辅助纳武利尤单抗联合瑞拉利单抗在可切除III/IV期黑色素瘤中显示持久无事件生存获益。
- 达到主要病理缓解的患者4年无事件生存率高达95%。
- 基线B7-H3表达升高与联合治疗耐药相关,为潜在可靶向标志物。
核心结论
- 新辅助序贯辅助纳武利尤单抗联合瑞拉利单抗治疗可切除III/IV期黑色素瘤具有长期获益,4年无事件生存率80%。
- 达到主要病理缓解的患者4年无事件生存率95%。
- 基线B7-H3表达升高与联合治疗耐药相关,为潜在可靶向的耐药预测标志物。
研究设计与样本
- II期临床试验(NCT02519322),纳入III/IV期可手术切除黑色素瘤患者,接受新辅助全身治疗后辅助纳武利尤单抗联合瑞拉利单抗。
- 更新随访中位47个月,评估长期生存及纵向生物标本基因表达。
主要发现
- 主要病理缓解率63%。
- 自新辅助开始4年时80%患者无事件,达MPR者95%无事件。
- 基线多个免疫调节通路上调与MPR相关;B7-H3表达升高与耐药相关。
关键数值与推荐
- 主要病理缓解定义为≤10%存活肿瘤。
- 中位随访47个月,4年无事件生存率80%(总体),95%(MPR患者)。
临床怎么用
- 支持新辅助纳武利尤单抗联合瑞拉利单抗作为可切除III/IV期黑色素瘤的治疗选择。
- 基线B7-H3表达可能用于识别联合治疗耐药风险较高的患者。
局限性
- II期临床试验,样本量未报告。
- 生物标志物分析为探索性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade (ICB) has revolutionized outcomes for patients with melanoma across multiple disease settings. In patients with advanced, unresectable disease, the ICB combination of nivolumab (anti-PD1) and relatlimab (anti-LAG-3) has demonstrated improved clinical outcomes compared with nivolumab monotherapy. There exists an unmet need to identify biomarkers that predict response to this combination regimen and rational therapeutic strategies to overcome resistance. We previously reported the initial results of a phase II clinical trial (ClinicalTrials.gov identifier: NCT02519322) of neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab, which achieved a major pathologic response (MPR; ≤10% viable tumor) rate of 63% in patients with stage III/IV, surgically resectable melanoma. Our updated clinical follow-up (median 47 months) for these patients demonstrates that at 4 years from the start of NST, 80% of patients remain event-free, including 95% of patients who achieved a MPR. Gene expression analysis of longitudinally collected biospecimens from the trial identifies baseline upregulation of several immune modulatory pathways associated with MPR; by contrast, increased B7-H3 expression was associated with resistance. This work demonstrates the long-term benefit of neoadjuvant nivolumab and relatlimab and identifies a potentially targetable predictor of resistance to this combination therapy.
引用
- Burton EM, Milton DR, Tetzlaff MT, et al. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol. 2025. PMID: 40638872. doi:10.1200/JCO-25-00494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。